RG Bretzel, U Nuber, W Landgraf, DR Owens, … - The Lancet, 2008 - Elsevier In the 44-week, parallel, open study that was undertaken in 69 study sites
across Europe and Australia, 418 patients with type 2 diabetes mellitus that was
inadequately controlled by oral hypoglycaemic agents were randomly assigned ... Cited by 50 - Related articles - All 24 versions
- ►leicestershirediabetes.org.uk [PDF] GT McMahon, RG Dluhy - The New England journal of medicine, 2007 - nejm.highwire.org The question of how to initiate insulin therapy in patients with type 2 diabetes
has become increasingly complicated as the range of insulin formulations with
differing time–activity profiles has expanded. Clinicians seeking to ... Cited by 19 - Related articles - BL Direct - All 11 versions
- ►nih.gov J Rosenstock, V Fonseca, JB McGill, M Riddle, … - Diabetologia, 2009 - Springer Abstract Aims/hypothesis This long-term study was designed to further
characterise the retinal safety profile of insulin glargine and human neutral
protamine Hagedorn (NPH) insulin in patients with type 2 diabetes mellitus. ... Cited by 15 - Related articles - All 10 versions
P Rossetti, F Porcellati, GB Bolli, CG Fanelli - Diabetes Care, 2008 - Am Diabetes Assoc Insulin therapy in diabetes, both at onset and after several years' duration, is
primarily directed to maintain near-normoglycemia to prevent the onset and/or
delay progression of long-term complications (1,2). However, it is ... Cited by 13 - Related articles - BL Direct - All 4 versions
DR Owens, GB Bolli - Diabetes Technology & Therapeutics, 2008 - liebertonline.com The new rDNA and DNA-derived “basal” insulin analogs, glargine and detemir,
represent significant ad- vancement in the treatment of diabetes compared with
conventional NPH insulin. This review describes blood glucose homeostasis ... Cited by 7 - Related articles - All 3 versions
SGHA Swinnen, F Holleman, JH DeVries - Diabetologia, 2008 - Springer Abstract Glucose clamp studies assessing the time–action profile of
long-acting insulin analogues have reported conflicting results. In an attempt
to reconcile the data, we organised an expert meeting of four leading ... Cited by 4 - Related articles - All 2 versions
T Heise, U Eckers, K Kanc, JN Nielsen, L … - Diabetes Technology & Therapeutics, 2008 - liebertonline.com Background: Type 2 diabetes patients on premixed insulin are commonly prescribed
biphasic insulin with low prandial insulin content, such as biphasic insulin
aspart (BIAsp) 30, comprising 30% insulin aspart (IAsp). The new ... Cited by 3 - Related articles - All 3 versions
MA Baxter - Acta Diabetologica, 2008 - Springer Abstract Intensive insulin therapy aimed at achieving normoglycaemia is becoming
increasingly accepted in the treatment of type 2 diabetes (T2DM) to reduce the
risk of diabetes-related complications. Insulin therapy is increas- ingly ... Cited by 3 - Related articles - All 3 versions
